Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patient Organizations Urge Zero Co-Pay Policy To Lower Biosimilars Cost

Stakeholders Request HHS And CMS To Eliminate Out-Of-Pocket Costs For Medicare Part B

Executive Summary

A group of organizations representing patients, consumers, providers and taxpayers have extended support to the zero co-pay policy which would decrease significant barriers for prescribing lower-cost biosimilars. The stakeholders have urged the US HHS and CMS to reform Medicare payment policies, “which would allow patients better access to lower cost biosimilars.”

You may also be interested in...

Amgen Urges Balance In US Biosimilars Policy

Amgen’s recent study on biosimilars trends has outlined the importance of US policy in the success of the biosimilars marketplace, insisting on the importance of increased competition and effective reimbursement and education policies. But with interests in innovative biologics as well as biosimilars, the company has also emphasized that pro-biosimilars policies must not stifle innovation and compromise free competition.

AAM Calls For A Balance Instead Of Banning Pay-For-Delay

US President Joe Biden has signed an executive order asking the FTC to ban so-called “pay-for-delay” reverse-payment settlements. According to the order, this could help curb high prices that are in part the result of lack of competition among drug manufacturers. However, talking exclusively to Generics Bulletin, AAM senior vice president Jeff Francer insists on a balance, explaining that such settlements result in earlier access to biosimilars and generics.

Generics Coverage Worsens Under Medicare Plans In 2021

Based on the latest AAM-sponsored study by Avalere Health, the US off-patent industry association has asked policymakers to initiate Medicare Part D reforms. Generic prescription drugs are only placed on generic tiers 45% of the time in 2021, a significant decrease from the 64% seen in 2016.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts